Predictika · Molecular diagnostics quotes

An AI sales agent's Biocartis Idylla quote, checked before it goes out

An AI sales agent prepares a quote for the Biocartis Idylla platform: Idylla Instruments and Consoles, Idylla Explore and Visualizer, the Idylla oncology tests (CE-IVD) and the Idylla research assays (Research Use Only), sold in boxes of six cartridges, with a service plan and a cartridge discount. Before it goes out, the agent sends it to Predictika, which checks it against a declarative model of the products, their regulatory status, specimen requirements and platform limits that Biocartis documents, and returns a verdict, every reason, a line-item quote and the figures it computed.

Scope: Biocartis Idylla platform quotes: Idylla Instrument and Console, Explore and Visualizer, seven Idylla CE-IVD oncology tests, ten Idylla research assays, service plans, cartridge discount and the stated total. See everything this validator covers

This validator models Idylla platform quotes as Biocartis documents the products on its public pages, not just the scenarios shown below.

  • Hardware and software — the Idylla Instrument and Idylla Console (one console connects up to eight instruments, counting instruments the lab already owns), Idylla Explore and Idylla Visualizer.
  • Cartridges — the CE-IVD tests Idylla BRAF, KRAS, NRAS-BRAF, MSI, CDx MSI, EGFR and GeneFusion Panel (article numbers A0010/6, A0020/6, A0030/6, A0100/6, A0220/6, A0270/6, A0120/6), and the Research Use Only assays BRAF, KRAS, NRAS-BRAF-EGFR S492R, MSI, EGFR, GeneFusion, POLE-POLD1, PIK3CA-AKT1, ctKRAS and ctEGFR, each sold in boxes of six cartridges.
  • Rules from the product pages — research assays are not for diagnostic procedures; minimum neoplastic cell content (50 percent for BRAF, 20 percent for MSI, CDx MSI and EGFR, 10 percent for KRAS, NRAS-BRAF and GeneFusion) unless the lab macrodissects; two FFPE sections for EGFR and three for GeneFusion on tissue under 20 square millimeters; 1 ml of plasma for ctKRAS and 2 ml for ctEGFR; availability of the CDx MSI Test to be checked with a Biocartis representative.
  • Commercial rules — the service plan on new instruments, instrument capacity for the busiest day, the cartridge discount limits, the software and service term, an order-value approval and the total the agent states.

Any Idylla platform quote that touches these products and rules is in scope — not only the scenarios pictured here. Not covered: the APIS kits, the Idylla ThyroidPrint Assay (shown by Biocartis as temporarily unavailable), the Idylla IDH1-2 Assay Kit, infectious disease assays (none are listed on the current Biocartis site), tax, shipping and country-specific availability. Biocartis publishes no prices or service plans; the prices and service plans shown are Predictika estimates for the demonstration.

The AI sales agentBuilds the Idylla platform quote from the conversation and says it is ready.
Predictika validatorChecks every rule at once and returns the verdict, each finding, and the computed figures.

7 scenarios in 3 groups · each group runs from the agent’s first attempt to the outcome · click one to switch

What the agent proposes

The AI sales agent says

Illustrative agent statement. The validator receives the structured request below.

Proposing agent: AI sales agent (scripted)

Before sending, the agent must call Recorded run

Predictika validator


      

        
        
        
      

      
Waiting for the call.

      
    

  

  
  

    
Where rules-based CPQ gets it wrong
Click to expand
    
Our assessment of what a typical rules-based CPQ (product rules, price rules and validation rules, as in Salesforce CPQ) does with the same cases. It is a judgment about effort and reliability, not a claim that nothing can be built.

    
What the validator caughtTypical rules-based CPQPredictika
Research assays quoted for patient testingOnly with care
Every Idylla assay is either CE-IVD or Research Use Only; a CPQ needs an intended-use field on the quote and a rule that compares it with a flag on each product, kept current as products are added.		Intended use is part of the request and every cartridge line is checked against it.
Specimen limits that depend on the testOnly with workarounds
Minimum neoplastic cell content, the number of FFPE sections, the small-biopsy rule and plasma volume are facts about the lab's specimens, not products, so a CPQ needs extra questions and a validation rule for each test.		The lab's specimen facts are fields of the request and are checked against each ordered test at once.
Consoles for the whole fleet, installed base includedOnly with care
One console connects up to eight instruments, so new instruments must be counted with the ones the lab already owns; that needs installed-base data in the quote.		Installed and new instruments and consoles are counted together in one pass.
Capacity for the busiest dayOnly with workarounds
Whether the instruments can finish the lab's busiest day is arithmetic on a workload figure, not on products; a CPQ has no natural place for it.		The workload is a field and capacity is computed from the whole fleet.
A total the agent statedOnly with workarounds
A CPQ prices the quote it holds; it does not compare that price with a total stated by an AI agent assembling the quote.		The stated total is a field and is compared with the computed total on every call.
Every problem returned in one answerOnly with workarounds
Rules tend to fire as the quote is saved or a step is completed, so a rep often fixes one error and meets the next.		All findings come back together, whatever order the choices arrived in.

  

  

    
What this validator catches: findings from its test cases
Click to expand
    
Every rule is checked on every call, in any order the choices arrive; one problem never hides another. Blocking findings stop the quote; approval findings need a person to sign off; everything else is computed.

    
1The Idylla BRAF Mutation Test needs at least 50 percent neoplastic cells, or macrodissection; the lab reports specimens with as little as 49 percent and the quote has no macrodissection.
2The Idylla MSI, CDx MSI and EGFR tests, and the MSI research assay, need at least 20 percent neoplastic cells, or macrodissection; the lab reports specimens with as little as 19 percent and the quote has no macrodissection.
3The Idylla CDx MSI Test is quoted; Biocartis asks that its availability be checked with a Biocartis representative, so a person should confirm.
4The Idylla KRAS, NRAS-BRAF and GeneFusion tests need at least 10 percent neoplastic cells, or macrodissection; the lab reports specimens with as little as 9 percent and the quote has no macrodissection.
5The Idylla EGFR Mutation Test uses two FFPE tissue sections per specimen; the lab supplies sections per specimen: 1.
6For tissue under 20 square millimeters the Idylla GeneFusion Panel and Assay use three 5 micrometer FFPE sections; the lab supplies sections per specimen: 2.
7The Idylla ctEGFR Mutation Assay needs 2 ml of plasma and the ctKRAS Mutation Assay needs 1 ml; the lab supplies plasma per sample in ml: 1.
8The Idylla ctEGFR Mutation Assay needs 2 ml of plasma and the ctKRAS Mutation Assay needs 1 ml; the lab supplies plasma per sample in ml: 0.
9The quote is for patient testing but includes research assays (boxes of research assays: 2); the Idylla research assays are for Research Use Only, not for use in diagnostic procedures.
10The quote runs 9 Idylla Instruments, new and already installed, on a total console count of 1; one Idylla Console connects up to eight instruments.
11The quote totals $401,200.00, above 400,000 dollars, so a person should confirm.
12The quote adds an Idylla Console but no Idylla Instrument, new or already installed, for it to run.
13The quote has cartridges but no Idylla Instrument, new or already installed, to run them in.
14The quote has Idylla Instruments but no Idylla Console, new or already installed, to connect them to.
15Idylla Explore or Idylla Visualizer is quoted without an Idylla Console to supply the run data.
16The lab expects 5 cartridge runs on its busiest day, but the instrument count is 2 and each instrument completes two runs in an eight-hour shift, because a result takes about three hours.
17The lab expects 9 cartridge runs on its busiest day, but the instrument count is 4 and each instrument completes two runs in an eight-hour shift, because a result takes about three hours.
18The quote adds new Idylla Instruments (count: 2) without a service plan; each new instrument needs the Standard, Extended or Premier plan.
19Software and service are quoted for 6 years; terms over five years are not on the price list, so a person should confirm.
20Software and service are quoted for 0 years; they are sold for at least one year.
21A cartridge discount of $576.01 on a cartridge list price of $7,200.00 is more than 8 percent; a sales manager should confirm.
22A cartridge discount of $1,080.00 on a cartridge list price of $7,200.00 is more than 8 percent; a sales manager should confirm.
23A cartridge discount of $1,080.01 on a cartridge list price of $7,200.00 is more than the 15 percent limit.
24Both the Idylla MSI Test and the Idylla CDx MSI Test are quoted; a person should confirm that the lab needs both.

  

  

    
Scenarios and results
Click to expand
    
The recorded result of the validator for each scenario on this page: the request the AI agent sent, the verdict, and every finding, in the order they appear above.

    
1. University hospital pathology lab: A quote for a university hospital pathology lab with colorectal and melanoma testing, a research assay and a cartridge discount

    
The agent's request. Please quote the Biocartis Idylla platform for a laboratory doing patient testing, with 3 new Idylla Instruments, 1 new Idylla Console, Idylla Explore, the Standard service plan, Idylla BRAF Mutation Test, 3 boxes, Idylla KRAS Mutation Test, 6 boxes, Idylla NRAS-BRAF Mutation Test, 4 boxes, Idylla MSI Test, 4 boxes and Idylla ctKRAS Mutation Assay, 2 boxes. Software and service run for 3 years. Its specimens contain at least 30 percent neoplastic cells. It supplies 1 ml of plasma per sample. It expects up to 7 cartridge runs on its busiest day. The quote includes a cartridge discount of $2,358.00. The quote states a total of $171,822.00. It is ready to send.

    
Verdict: Blocked.

    
    
      
  • Research assays quoted for patient testing. The quote is for patient testing but includes research assays (boxes of research assays: 2); the Idylla research assays are for Research Use Only, not for use in diagnostic procedures.
    • 
      
  • Neoplastic cell content too low for BRAF. The Idylla BRAF Mutation Test needs at least 50 percent neoplastic cells, or macrodissection; the lab reports specimens with as little as 30 percent and the quote has no macrodissection.
    • 
      
  • Not enough instrument capacity for the busiest day. The lab expects 7 cartridge runs on its busiest day, but the instrument count is 3 and each instrument completes two runs in an eight-hour shift, because a result takes about three hours.
    • 
      
  • Stated total does not match. The quote states a total of $171,822.00; the estimated list prices give $181,622.00.
    • 
      
  • Cartridge discount above 8 percent. A cartridge discount of $2,358.00 on a cartridge list price of $23,580.00 is more than 8 percent; a sales manager should confirm.
    • 
    

    
2. University hospital pathology lab: The agent resubmits after fixing the errors

    
The agent's request. Please quote the Biocartis Idylla platform for a laboratory doing patient testing, with 4 new Idylla Instruments, 1 new Idylla Console, Idylla Explore, the Standard service plan, Idylla BRAF Mutation Test, 3 boxes, Idylla KRAS Mutation Test, 6 boxes, Idylla NRAS-BRAF Mutation Test, 4 boxes and Idylla MSI Test, 4 boxes. Software and service run for 3 years. Its specimens contain at least 30 percent neoplastic cells, and it will macrodissect. It supplies 1 ml of plasma per sample. It expects up to 7 cartridge runs on its busiest day. The quote includes a cartridge discount of $2,058.00. The quote states a total of $226,722.00. It is ready to send.

    
Verdict: Needs approval.

    
    
      
  • Cartridge discount above 8 percent. A cartridge discount of $2,058.00 on a cartridge list price of $20,580.00 is more than 8 percent; a sales manager should confirm.
    • 
      
  • Quote summary. A term total of $226,722.00 at the estimated list prices.
    • 
    

    
3. University hospital pathology lab: The agent resubmits after fixing the errors

    
The agent's request. Please quote the Biocartis Idylla platform for a laboratory doing patient testing, with 4 new Idylla Instruments, 1 new Idylla Console, Idylla Explore, the Standard service plan, Idylla BRAF Mutation Test, 3 boxes, Idylla KRAS Mutation Test, 6 boxes, Idylla NRAS-BRAF Mutation Test, 4 boxes and Idylla MSI Test, 4 boxes. Software and service run for 3 years. Its specimens contain at least 30 percent neoplastic cells, and it will macrodissect. It supplies 1 ml of plasma per sample. It expects up to 7 cartridge runs on its busiest day. The quote includes a cartridge discount of $1,646.40. The quote states a total of $227,133.60. It is ready to send.

    
Verdict: Allowed.

    
    
      
  • Quote summary. A term total of $227,133.60 at the estimated list prices.
    • 
    

    
4. Regional reference laboratory: A quote for a regional reference laboratory expanding its lung and colorectal testing on top of six installed instruments

    
The agent's request. Please quote the Biocartis Idylla platform for a laboratory doing patient testing, with 4 new Idylla Instruments, Idylla Explore, Idylla Visualizer, Idylla KRAS Mutation Test, 8 boxes, Idylla NRAS-BRAF Mutation Test, 6 boxes, Idylla MSI Test, 6 boxes, Idylla GeneFusion Panel, 6 boxes and Idylla EGFR Mutation Test, 6 boxes. The laboratory already has 6 Idylla Instruments on 1 Idylla Console. Software and service run for 2 years. Its specimens contain at least 25 percent neoplastic cells. It supplies 1 FFPE section per specimen, and its lung biopsies are small. It expects up to 18 cartridge runs on its busiest day. The quote includes a cartridge discount of $2,743.20. The quote states a total of $204,176.80. It is ready to send.

    
Verdict: Blocked.

    
    
      
  • Too many instruments for the consoles. The quote runs 10 Idylla Instruments, new and already installed, on a total console count of 1; one Idylla Console connects up to eight instruments.
    • 
      
  • Too few tissue sections for EGFR. The Idylla EGFR Mutation Test uses two FFPE tissue sections per specimen; the lab supplies sections per specimen: 1.
    • 
      
  • Too few tissue sections for a small biopsy. For tissue under 20 square millimeters the Idylla GeneFusion Panel and Assay use three 5 micrometer FFPE sections; the lab supplies sections per specimen: 1.
    • 
      
  • New instruments without a service plan. The quote adds new Idylla Instruments (count: 4) without a service plan; each new instrument needs the Standard, Extended or Premier plan.
    • 
    

    
5. Regional reference laboratory: The agent resubmits after fixing the errors

    
The agent's request. Please quote the Biocartis Idylla platform for a laboratory doing patient testing, with 4 new Idylla Instruments, 1 new Idylla Console, Idylla Explore, Idylla Visualizer, the Premier service plan, Idylla KRAS Mutation Test, 8 boxes, Idylla NRAS-BRAF Mutation Test, 6 boxes, Idylla MSI Test, 6 boxes, Idylla GeneFusion Panel, 6 boxes and Idylla EGFR Mutation Test, 6 boxes. The laboratory already has 6 Idylla Instruments on 1 Idylla Console. Software and service run for 2 years. Its specimens contain at least 25 percent neoplastic cells. It supplies 3 FFPE sections per specimen, and its lung biopsies are small. It expects up to 18 cartridge runs on its busiest day. The quote includes a cartridge discount of $2,743.20. The quote states a total of $337,976.80. It is ready to send.

    
Verdict: Allowed.

    
    
      
  • Quote summary. A term total of $337,976.80 at the estimated list prices.
    • 
    

    
6. Cancer research institute: A quote for a cancer research institute with liquid biopsy and tissue research assays

    
The agent's request. Please quote the Biocartis Idylla platform for a laboratory doing research, with 2 new Idylla Instruments, Idylla Explore, the Standard service plan, Idylla NRAS-BRAF-EGFR S492R Mutation Assay, 4 boxes, Idylla POLE-POLD1 Mutation Assay, 2 boxes, Idylla PIK3CA-AKT1 Mutation Assay, 2 boxes, Idylla ctKRAS Mutation Assay, 2 boxes and Idylla ctEGFR Mutation Assay, 3 boxes. Software and service run for 2 years. It supplies 1 ml of plasma per sample. It expects up to 4 cartridge runs on its busiest day. The quote includes a cartridge discount of $945.00. The quote states a total of $112,155.00. It is ready to send.

    
Verdict: Blocked.

    
    
      
  • Instruments without a console. The quote has Idylla Instruments but no Idylla Console, new or already installed, to connect them to.
    • 
      
  • Software without a console. Idylla Explore or Idylla Visualizer is quoted without an Idylla Console to supply the run data.
    • 
      
  • Not enough plasma for the liquid biopsy assays. The Idylla ctEGFR Mutation Assay needs 2 ml of plasma and the ctKRAS Mutation Assay needs 1 ml; the lab supplies plasma per sample in ml: 1.
    • 
    

    
7. Cancer research institute: The agent resubmits after fixing the errors

    
The agent's request. Please quote the Biocartis Idylla platform for a laboratory doing research, with 2 new Idylla Instruments, 1 new Idylla Console, Idylla Explore, the Standard service plan, Idylla NRAS-BRAF-EGFR S492R Mutation Assay, 4 boxes, Idylla POLE-POLD1 Mutation Assay, 2 boxes, Idylla PIK3CA-AKT1 Mutation Assay, 2 boxes, Idylla ctKRAS Mutation Assay, 2 boxes and Idylla ctEGFR Mutation Assay, 3 boxes. Software and service run for 2 years. It supplies 2 ml of plasma per sample. It expects up to 4 cartridge runs on its busiest day. The quote includes a cartridge discount of $945.00. The quote states a total of $121,955.00. It is ready to send.

    
Verdict: Allowed.

    
    
      
  • Quote summary. A term total of $121,955.00 at the estimated list prices.
    • 
    

  

  

    
Narration transcript
Click to expand
    
The text of the narrated walkthrough, step by step.

    
    
      
  1. Welcome to a demo of Predictika's Validator. An AI sales agent prepares a quote for the Biocartis Idylla platform: Idylla Instruments and Consoles, Idylla Explore and Visualizer, the Idylla oncology tests (CE-IVD) and the Idylla research assays (Research Use Only), and more. Before it goes out, the agent sends it to Predictika, which checks it against a declarative model of the products, their regulatory status, specimen requirements and platform limits that Biocartis documents, and returns a verdict, every reason, a line-item quote and the figures it computed.
    2. 
      
  2. I will start with the first request by the agent.
    3. 
      
  3. The agent says. Please quote the Biocartis Idylla platform for a laboratory doing patient testing, with 3 new Idylla Instruments, 1 new Idylla Console. Software and service run for 3 years. The rest of the request is on screen. The quote states a total of $171,822.00.
    4. 
      
  4. Before it goes out, the agent calls the validator.
    5. 
      
  5. Blocked, with four findings and one approval, all in one answer. The quote is for patient testing but includes research assays (boxes of research assays: 2); the Idylla research assays are for Research Use Only, not for use in diagnostic procedures. The Idylla BRAF Mutation Test needs at least 50 percent neoplastic cells, or macrodissection; the lab reports specimens with as little as 30 percent and the quote has no macrodissection. The lab expects 7 cartridge runs on its busiest day, but the instrument count is 3 and each instrument completes two runs in an eight-hour shift, because a result takes about three hours. The other one is on screen.
    6. 
      
  6. The validator returned four blocking findings and one approval in one answer. A check that reads one field at a time would pass most of this; it shows only when the choices in the quote are checked against each other and against the stated total.
    7. 
      
  7. What this shows: for research assays quoted for patient testing, a rules-based CPQ is error-prone for this.
    8. 
      
  8. Now the agent resubmits.
    9. 
      
  9. The corrected request. It changes the New Idylla Instruments to 4, the macrodissection to yes, the cartridge discount to $2,058.00 and the stated total to $226,722.00. It removes the idylla ctKRAS Mutation Assay.
    10. 
      
  10. It calls the validator again.
    11. 
      
  11. Not blocked, but held for a person.
    12. 
      
  12. The validator also returns the line-item quote. It starts with Idylla Instrument and Idylla Console; the other six lines are on screen.
    13. 
      
  13. The four blocking findings are cleared; one approval remains for a person: cartridge discount above 8 percent.
    14. 
      
  14. The agent resubmits once more.
    15. 
      
  15. The revised request. It changes the cartridge discount to $1,646.40 and the stated total to $227,133.60.
    16. 
      
  16. It calls the validator once more.
    17. 
      
  17. This time the validator clears it.
    18. 
      
  18. The validator also returns the line-item quote. It starts with Idylla Instrument and Idylla Console; the other six lines are on screen.
    19. 
      
  19. The earlier finding is cleared, and the validator's total, $227,133.60, matches the quote.
    20. 
      
  20. Five problems caught in one call, fixed in two passes, and a clean $227,133.60 quote. That is the value of Predictika's validator: catching mistakes before they reach the customer. Now you can try the other scenarios yourself.
    21.